Skip to main content

Table 2 PheWAS using Cox regression was conducted to investigate the relationship between MAFLD and causes of death in males and females

From: Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank

Causes of death

Total (N = 326,606)

Female (N = 122,626)

Male (N = 203,980)

No.a

HR (95% CI)

No.a

HR (95% CI)

No.a

HR (95% CI)

Cardiovascular death

6025

1.64 (1.58–1.71)

1603

1.97 (1.81–2.14)

4422

1.55 (1.48–1.62)

Digestive system death

1409

1.81 (1.66–1.98)

441

2.30 (1.95–2.73)

968

1.65 (1.49–1.83)

Endocrine system death

2007

3.23 (2.95–3.53)

605

4.04 (3.38–4.83)

1402

2.97 (2.67–3.29)

Genitourinary system death

1203

2.05 (1.86–2.26)

383

2.49 (2.07–3.01)

820

1.89 (1.68–2.12)

Infectious and parasitic death

867

1.63 (1.46–1.80)

332

1.60 (1.35–1.90)

535

1.50 (1.31–1.71)

Malignant neoplasms death

7488

1.26 (1.21–1.30)

2556

1.28 (1.21–1.36)

4932

1.24 (1.19–1.30)

Respiratory system death

3606

1.21 (1.15–1.27)

1070

1.50 (1.36–1.65)

2536

1.12 (1.05–1.18)

Unnatural cause death

1083

1.21 (1.11–1.32)

280

1.45 (1.21–1.75)

803

1.14 (1.03–1.27)

  1. After Bonferroni correction, a total of 8 causes of death were significantly associated with MAFLD
  2. HR hazard ratio, CI confidence interval, MAFLD metabolic dysfunction-associated fatty liver disease
  3. aNumber of MAFLD participants who died due to the corresponding causes, including primary and secondary causes of death